Tap to Read ➤

Covaxin Is More Effective Against Delta Plus Variant, says ICMR

A new ICMR study showed that Bharat Biotech's Covaxin is more effective and retains a significant efficacy against the severity of delta plus Covid-19 variant or AY.1.
In this study, antibody activity has been observed in emerging variants such as delta, delta plus, and the B1.617.3 strains.
As per the study IgG, antibody titer, and the neutralizing potential of full doses of BBV152 vaccine is more effective against all delta variants.
Previously Covaxin has demonstrated 77.8% effectiveness against symptomatic covid 19 and 65.2% protection against delta variant.
Though the neutralizing property of the antibodies has been reduced, but still effective against delta plus variants, said Dr. Samiran Panda, the Head of Epidemiology and Communicable Diseases at ICMR.